Stakeholders Find Interim FDA Commissioner 'a Troubling Choice'

Drug Industry Daily
KEYWORDS FDA
A A

The Bush administration’s choice of Andrew von Eschenbach to be the interim FDA commissioner is raising concerns amongst various stakeholders, who say his role as director of the National Cancer Institute (NCI) and his alleged decision to continue to run that group shows a lack of the necessary objectivity and dedication needed to run the FDA.

To View This Article:

Login

Subscribe To Drug Industry Daily